Results: 11
Sotrovimab: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 4, p. 477, doi. 10.1007/s40265-022-01690-7
- By:
- Publication type:
- Article
Drug Repurposing to Target Neuroinflammation and Sensory Neuron-Dependent Pain.
- Published in:
- Drugs, 2022, v. 82, n. 4, p. 357, doi. 10.1007/s40265-022-01689-0
- By:
- Publication type:
- Article
Correction to: Pharmacological Approaches to Managing Violence and Aggression in Prison Populations: Clinical and Ethical Issues.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Molnupiravir: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 4, p. 455, doi. 10.1007/s40265-022-01684-5
- By:
- Publication type:
- Article
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
- Published in:
- Drugs, 2022, v. 82, n. 4, p. 439, doi. 10.1007/s40265-022-01683-6
- By:
- Publication type:
- Article
Olverembatinib: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 4, p. 469, doi. 10.1007/s40265-022-01680-9
- By:
- Publication type:
- Article
Tezepelumab: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 4, p. 461, doi. 10.1007/s40265-022-01679-2
- By:
- Publication type:
- Article
Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.
- Published in:
- Drugs, 2022, v. 82, n. 4, p. 407, doi. 10.1007/s40265-022-01676-5
- By:
- Publication type:
- Article
Authors' Reply to Colak et al.: "Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing".
- Published in:
- 2022
- By:
- Publication type:
- Letter
Comment on: "Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing".
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction.
- Published in:
- Drugs, 2022, v. 82, n. 4, p. 375, doi. 10.1007/s40265-021-01666-z
- By:
- Publication type:
- Article